Everything you knew about bioabsorbable polymer stents has changed.

MiStent is the only stent which is tailored to the vessel response, optimising patient outcomes by ensuring sustained drug release long after its polymer coating is absorbed, thanks to its unique crystalline drug release technology.

MiStent is a registered trademark of Micell Technologies, Inc.


Unique Crystalline Drug Delivery

MiStent SES delivers sirolimus, in a crystalline form, to the tissue. This unique method of delivery allows for a sustained drug presence that is maintained after the polymer is absorbed.

  • Gradual, Linear and Long-Term Elution Profile


    Unique to MiStent SES sirolimus is maintained in a microcrystalline matrix and elution is sustained up to 9 months, as opposed to a conventional DES which utilises an amorphous form of drug and a much shorter elution period.


    *Tissue Assay is unable to differentiate between crystalline and dissolved drug, therefore this chart is only an estimation and is representative.

    1. Adapted from Balakrishnan, B., et al.; Intravascular drug release kinetics dictate arterial drug deposition, retention, and disrubution. J. Control. Release, 123 (2) (2007), p. 100-108.

    2. Adapted from Carlyle. W., et al.; Enhanced drug delivery capabilities from stents coated with absorbable polymer and crystalline drug. J. Control. Release, 162 (3) (2012), p. 561-567.

  • Rapid Polymer Absorption with Sustained Drug Presence

  • Thin Strut Design


    *Adapted from Dawkins, K., oral presentation at TCT 2014 and relevant product websites accessed in January 2015. 

  • Outstanding Acute Performance


    *Deliverability is defined as 100 / the average of the forces required to Insert, Track, Retract and Withdraw the stent delivery catheter through a 90 angle, a tortuous anatomy model and a guide catheter. 

    Third Party Independent Lab bench data on file at Micell Technologies, Inc.

  • Rapid Strut Coverage


    Uncovered struts are predictive of late stent thrombosis1


    1. Finn A, et al, Pathological correlates of late drug-eluting stent thrombosis: strut coverage as a marker of endothelialization. Circulation, 2007 May 8; 115(18): 2435-41.

    2. Ormiston, J., et al.; First-in-Human Evaluation of a Bioabsorbable Polymer-Coated Sirolimus-Eluting Stent. JACC CI. 2013 6 (10), 1026-1033. 

    3. Attizzani G, et al. Serial Assessment by Optical Coherence Tomography of Early and Late Vascular Responses After Implantation of an Absorbable-Coating Sirolimus-Eluting Stent (from the First-in-Human DESSOLVE 1 Trial) Am J Cardiol 2013; 112:1557-1564

  • Low Late Lumen Loss and Progression


    The graph on the left shows Independent angiographic core lab analysis by Cardialysis comparing MiStent DESSOLVE II and Xience Spirit II study data.

  • Slow Progression of TLR over Time


    1. Stone G, et al, 5-Year Results of a Randomised Comparison of XIENCE V Everolimus-Eluting and TAXUS Paclitaxel-Eluting; JACC: CI (6, 12) 2013, Pages 1263-1266 Stents

    2. Onuma Y, el al. Five-year long-term clinical follow-up of the XIENCE V everolimus-eluting coronary stent system in the treatment of patients with de novo coronary artery disease: the SPIRIT II trial. EuroIntervention 2013;8:1047-1051

    3. Ormiston J, Three Year Results of the DESSOLVE I first-in-human trial and the DESSOLVE II randomized trial of a sirolimus-eluting stent with fully absorbable polymer. J Am Coll Cardiol. 2014;64(16_S):. doi:10.1016/j.jacc.2014.06.636

  • Proven Long Term Safety


    1. W. Wijns, et al. Evaluation of a crystalline sirolimus-eluting coronary stent with a bioabsorbable polymer designed for rapid dissolution: two-year outcomes from the DESSOLVE I and II trials, Eurointervention 2015; Spetember 2015

    2. J. Ormiston. three Year Results of the DESSOLVE I first-in-human trial and the DESSOLVE II randomized trial of a sirolimus-eluting stent with fully absorbable polymer. Oral presentation at TCT 2014

  • Product codes


    Guidewire compatibility 0.014” (0.35mm).

    2.5, 2.75, 3.0mm diameters are compatible with a 5F (1.7mm) Guiding Catheter,

    3.5mm diameters are compatible with a 6F (2.0mm) Guiding Catheter

  • Resources



    MiStent’s unique mechanism of crystalline drug delivery provides controlled and sustained elution to limit disease progression avoiding TLR catch-up.

    Download File


    DESSOLVE III data, presented at EuroPCR 2017

    Download File

Contact Us

Get in touch for the latest product information.

Contact Us

Page ID 1231   |   Last edited 2017/11/10